Skip to main content

Table 2 Regression analysis of progression-free survival according to SNAI2 level and clinicopathological characteristics

From: SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

  Cohort 1 Cohort 2
Variable Hazard ratio (95% CI) p Hazard ratio (95% CI) p
SNAI2 level 2.11 (1.21–3.66) 0.008 1.92 (1.03–3.59) 0.04
Age at metastasis 2.19 (0.37–12.95) 0.39 0.90 (0.33–2.49) 0.85
Site of relapse 1.47 (0.98–2.21) 0.07 0.85 (0.56–1.31) 0.47
HER2 status of metastasis 1.46 (0.50–4.28) 0.49 1.49 (0.34–6.52) 0.60
  1. HER2 human epidermal growth factor receptor 2